OvaScience (OVAS) Lifted to “Buy” at ValuEngine

ValuEngine upgraded shares of OvaScience (NASDAQ:OVAS) from a hold rating to a buy rating in a research report sent to investors on Thursday.

NASDAQ:OVAS traded up $0.12 during trading hours on Thursday, hitting $0.79. 239,900 shares of the company were exchanged, compared to its average volume of 358,711. OvaScience has a 52-week low of $0.66 and a 52-week high of $1.60.

OvaScience (NASDAQ:OVAS) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.14) earnings per share for the quarter. The company had revenue of $0.08 million for the quarter. OvaScience had a negative return on equity of 47.19% and a negative net margin of 11,175.59%.

An institutional investor recently raised its position in OvaScience stock. Wells Fargo & Company MN raised its holdings in shares of OvaScience Inc (NASDAQ:OVAS) by 217.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 473,876 shares of the biotechnology company’s stock after acquiring an additional 324,685 shares during the period. Wells Fargo & Company MN owned approximately 1.33% of OvaScience worth $384,000 at the end of the most recent quarter. 20.56% of the stock is currently owned by institutional investors and hedge funds.

OvaScience Company Profile

OvaScience, Inc, a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women's fertility.

See Also: How to Invest in a Bull Market

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply